Drug Profile
Radiolabelled somatostatin peptides
Alternative Names: MK 678-derived somatostatin peptides; Seglitide analogue; Somatoscan; Somatostatin peptides; Somatostatin TherapyLatest Information Update: 13 Sep 2007
Price :
$50
*
At a glance
- Originator DRAXIS Specialty Pharmaceuticals
- Class Antineoplastics; Cyclic peptides; Peptide diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 13 Sep 2007 No development reported - Preclinical for Cancer diagnosis in Canada (unspecified route)
- 13 Sep 2007 No development reported - Preclinical for Cancer in Canada (unspecified route)
- 10 Feb 2005 Preclinical trials in Cancer diagnosis in Canada (unspecified route)